Neurobiological Technologies, Inc.

is a biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates.

Corporate Spotlight

May 14, 2008
Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 

May 12, 2008
Neurobiological Technologies Reports Third Quarter Financial Results 

NASDAQ:: NTII
     

Clinical Trials

XERECEPT® Phase III Trials for the Treatment of Peritumoral Brain Edema

Viprinex Phase III Trials for the Treatment of Acute Ischemic Stroke

View Clinical Trial Educational Film Trailer
(5 minutes)


About NTIProductsPipelineInvestorsNews & InformationContact Us
Change Font Size:                  Print This Page: 
Home | Site Map | Glossary |  Search      
© 2006 Neurobiological Technologies, Inc.built@zoomedia.com